The 177Lu versions of F19 and A33 mAbs were prepared as control agents, and the potential of the ESC11 and ESC14 radiopharmaceuticals were assessed using SPECT/CT imaging, efficacy studies, and the FAP+ and FAP− melanoma cell lines SK-MEL-187 and SK-MEL-16, respectively. The gene discussed is FAP; the disease is melanoma.